A PHASE I DOSE-ESCALATION STUDY OF WEEKLY IMC-1121B, A FULLY HUMAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (VEGFR2) IGG1MONOCLONAL ANTIBODY (MAB), IN PATIENTS (PTS) WITH ADVANCED CANCER

CAMIDGE, D.R., & ECKHARDT, S.G.. (2006). A PHASE I DOSE-ESCALATION STUDY OF WEEKLY IMC-1121B, A FULLY HUMAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (VEGFR2) IGG1MONOCLONAL ANTIBODY (MAB), IN PATIENTS (PTS) WITH ADVANCED CANCER. JOURNAL OF CLINICAL ONCOLOGY, 24(-), 30-32. SID. https://sid.ir/paper/652706/en

CAMIDGE D.R., ECKHARDT S.G.. A PHASE I DOSE-ESCALATION STUDY OF WEEKLY IMC-1121B, A FULLY HUMAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (VEGFR2) IGG1MONOCLONAL ANTIBODY (MAB), IN PATIENTS (PTS) WITH ADVANCED CANCER. JOURNAL OF CLINICAL ONCOLOGY[Internet]. 2006;24(-):30-32. Available from: https://sid.ir/paper/652706/en

D.R. CAMIDGE, and S.G. ECKHARDT, “A PHASE I DOSE-ESCALATION STUDY OF WEEKLY IMC-1121B, A FULLY HUMAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (VEGFR2) IGG1MONOCLONAL ANTIBODY (MAB), IN PATIENTS (PTS) WITH ADVANCED CANCER,” JOURNAL OF CLINICAL ONCOLOGY, vol. 24, no. -, pp. 30–32, 2006, [Online]. Available: https://sid.ir/paper/652706/en